Business Wire19 天
Blue Lake Biotechnology Reports Additional Promising Clinical Data from Ongoing Pediatric ...
Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored ...
Yahoo Finance23 天
First Subject Dosed in Initial Cohort of Phase 2b Clinical Study of CyanVac’s Intranasal ...
December 09, 2024--(BUSINESS WIRE)--CyanVac LLC, a clinical-stage biotechnology company developing intranasal ... administered to dogs as part of combination distemper/kennel cough vaccines ...
Business Wire1 个月
Blue Lake and CyanVac Report Positive Phase 2a Data for Intranasal COVID-19 Vaccine Candidate
a clinical-stage intranasal vaccine company developing ... which has been commonly administered to dogs as part of combination distemper/kennel cough vaccines for decades. CyanVac and its ...